This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liang, Y. Articles by Cao, G. Search for Related Content PubMed PubMed Citation Articles by Liang, Y. Articles by Cao, G.

Liver X Receptors (LXRs) Regulate Apolipoprotein AIV-Implications of the Antiatherosclerotic Effect of LXR Agonists

Lilly Research Laboratories (Y.L., T.P.B., H.G., T.P.R., S.D.L., P.I.E., G.C.), Eli Lilly & Company, Indianapolis, Indiana 46285; Department of Anatomy and Cell Biology (X.-C.J., R.L.), SUNY Downstate Medical Center, Brooklyn, New York 11203; and Department of Molecular Genetics (G.L.), University of Texas Southwestern Medical Center, Dallas, Texas 75390-9046

Address all correspondence and requests for reprints to: Guoqing Cao, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana 46285. E-mail: Guoqing_Cao{at}lilly.com.

Liver X receptors (LXRs) regulate target genes that are critical in lipoprotein metabolism and atherosclerosis. Apolipoprotein AIV (ApoAIV) is an apolipoprotein that is associated with chylomicrons and high-density lipoproteins. Plasma ApoAIV level in humans is inversely correlated with coronary artery events and overexpression of ApoAIV in mice results in significant reduction in atherosclerosis. We report here that LXRs directly regulate apoAIV at the transcriptional level. Treatment of C57B6 mice with a synthetic LXR agonist, T0901317, resulted in significant increases in plasma apoAIV that was associated with high-density lipoprotein. Examination of both intestinal and liver apoAIV mRNA revealed specific increases in liver mRNA only. In a human heptoma HepG2 cell model, apoAIV mRNA was up-regulated upon the treatment with either native or synthetic LXR agonists. Nuclear run-on study revealed a significant increase in the ApoAIV transcriptional rate upon LXR activation. Examination of the human apoAIV proximal promoter revealed a potential LXR response element that demonstrated binding with HepG2 nuclear extracts. Cotransfection studies in HepG2 cells indicated that this responsive element was functional in mediating the human ApoAIV gene response to LXR agonists. In addition, we identified a functional LXR-responsive element at 3' end enhancer region of mouse ApoAIV gene. We conclude that ApoAIV is a direct target gene of LXRs that may contribute to the antiatherogenic effect of LXR activation.

NURSA Molecule Pages Link:

Nuclear Receptors:   LXRβ  |  LXRα

Ligands:   22α-Hydroxycholesterol  |  T0901317  |  9-cis-Retinoic acid

This article has been cited by other articles:

				S. Colin, E. Bourguignon, A.-B. Boullay, J.-J. Tousaint, S. Huet, F. Caira, B. Staels, S. Lestavel, J.-M. A. Lobaccaro, and P. Delerive Intestine-Specific Regulation of PPAR{alpha} Gene Transcription by Liver X Receptors Endocrinology, October 1, 2008; 149(10): 5128 - 5135. [Abstract] [Full Text] [PDF]

				F. Blaschke, Y. Takata, E. Caglayan, A. Collins, P. Tontonoz, W. A. Hsueh, and R. K. Tangirala A Nuclear Receptor Corepressor-Dependent Pathway Mediates Suppression of Cytokine-Induced C-Reactive Protein Gene Expression by Liver X Receptor Circ. Res., December 8, 2006; 99(12): e88 - e99. [Abstract] [Full Text] [PDF]

				E. A. Hanniman, G. Lambert, Y. Inoue, F. J. Gonzalez, and C. J. Sinal Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4{alpha}, and PGC-1{alpha} J. Lipid Res., November 1, 2006; 47(11): 2503 - 2514. [Abstract] [Full Text] [PDF]

				R. J. Schmidt, J. V. Ficorilli, Y. Zhang, K. S. Bramlett, T. P. Beyer, K. Borchert, M. S. Dowless, K. A. Houck, T. P. Burris, P. I. Eacho, et al. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity J. Lipid Res., May 1, 2006; 47(5): 1037 - 1044. [Abstract] [Full Text] [PDF]

				T. Hu, P. Foxworthy, A. Siesky, J. V. Ficorilli, H. Gao, S. Li, M. Christe, T. Ryan, G. Cao, P. Eacho, et al. Hepatic Peroxisomal Fatty Acid {beta}-Oxidation Is Regulated by Liver X Receptor {alpha} Endocrinology, December 1, 2005; 146(12): 5380 - 5387. [Abstract] [Full Text] [PDF]

				J. C. Carrier, G. Deblois, C. Champigny, E. Levy, and V. Giguere Estrogen-related Receptor {alpha} (ERR{alpha}) Is a Transcriptional Regulator of Apolipoprotein A-IV and Controls Lipid Handling in the Intestine J. Biol. Chem., December 10, 2004; 279(50): 52052 - 52058. [Abstract] [Full Text] [PDF]